These are the stocks posting the largest moves before the bell.Market Insiderread more
The next three weeks are among the rockiest, on a historical basis, of the entire calendar.Trading Nationread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
Worries over global economic growth were set to thwart Wall Street's run to record highs on Monday.Marketsread more
Guggenheim reiterated its buy rating on Boston Beer Company's stock and raised its price target to $462 from $449 per share.Investingread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
Ad-tech company The Trade Desk is launching a campaign to show how it differs from tech giants like Google and Facebook.Technologyread more
The streaming wars may have claimed a new victim, and one technical analyst says it could be about to get worse.Trading Nationread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.Singapore Summitread more
No quid pro quo, there was nothing," Trump said the call. "It was a perfect conversation."Politicsread more
There will be winners and losers in the stock market following Republicans and Democrats splitting Congress in the 2018 midterm elections.
The big winner could be the stock market overall as a hamstrung government leaves in place much of what President Donald Trump has accomplished, but also keeps in check on some of his more extreme actions like trade battles. Stock futures pointed to a triple-digit gain for the Dow Jones Industrial Average on Wednesday.
Industrial and materials stocks could be among the best performers on speculation politicians can broker an infrastructure deal, Wall Street analysts and strategists speculated before the election. Drug stocks could come under pressure on a bipartisan plan to rein in drug prices.
A check on trade tensions: Good for stocks
With Democrats controlling the lower chamber of a split government, Trump could be forced to soften his aggressive trade strategy with China. The trade war between the two nations has roiled markets and often left investors on edge about the future between the world's two largest economic powerhouses.
Shares of Caterpillar, which had taken a hit from Trump's trade war with China, rose 4.4 percent Wednesday.
"Our base case of the Democrats taking over the House holds the potential to reduce downside risks from trade policy friction," Deutsche Bank's chief equity strategist Binky Chadha wrote last week. "Congressional investigations and potential impeachment proceedings, even though nominal, would likely use up significant bandwidth while a growing number of Democrats and even Republicans are likely to attempt reducing Presidential power in dealing with trade."
A reduction in trade tensions between Washington and Beijing allows the market to refocus on strong U.S. growth, Chadha added, as well as ease pressure on global growth and lead to a "stronger eventual rally."
The White House imposed tariffs of 10 percent on $200 billion of Chinese products in September, with the rate set to increase to 25 percent by the end of the year unless the countries can reach a breakthrough in the trade talks. In response, Beijing said it would impose taxes on 5,207 U.S. imports worth about $60 billion.
The two nations had already imposed tariffs on $50 billion of each other's goods before the September sanctions.
Dan Clifton, head of policy research at Strategas Research, said Trump will now start looking ahead to his own re-election and continue to seek policies to help the economy.
"I think it starts at the G-20 meeting with China," Clifton said. "It looks like the president could do something big on trade."
Bipartisan support for infrastructure: Upside for materials, industrials, energy
Though Republicans and Democrats disagree on a wide variety of policy proposals, members of both parties have been supportive of infrastructure reform. Any progress on that front could be profitable for companies exposed to public work projects, such as machinery manufacturers, steel producers and oil and gas providers.
"The Democrats are likely to push plans for large-scale infrastructure spending. Republicans have generally opposed Democratic plans on this issue, but President Trump has expressed support for infrastructure spending and might be willing to help," HSBC chief U.S. economist Kevin Logan wrote in a note in October.
Materials, industrials and energy stocks "could benefit from a small infrastructure bill under Democrats, a weaker U.S. Dollar and reduced trade tensions," Bank of America Chief Equity Strategist Savita Subramanian wrote in September.
Pharmaceuticals: A common target?
Strategists speculated Congress and Trump could find common ground on reducing drug prices, a potential headwind for health care and drugmakers specifically.
Morgan Stanley policy strategist Michael Zezas pointed to House Minority Leader Nancy Pelosi's mention of pharmaceuticals last night, saying it "was really the only issue that she mentioned" during her victory speech last night.
"It's entirely possible the Democrats might try and prioritize something around prescription drug pricing which, at least in name, the president seems to agree with Democrats on," Zezas said. "So I think that's a sector you've got to continue to look at that might have some pressure."
Fundstrat's Thomas Block added in a note Wednesday, "In my view one of the business sectors that could take a lot of heat is Pharma."
"Trump has often sided with Democrats on allowing importation of drugs from other nations that control the prices. Also Trump in the past has expressed support for the idea of allowing the federal government to use its marketplace leverage to negotiate lower Medicare prices with pharmaceutical companies, another idea long advocated by Democrats," Block wrote.